TY - JOUR
T1 - Microencapsulated foods as a functional delivery vehicle for omega-3 fatty acids: a pilot study
AU - Earnest, Conrad P
AU - Hammar, M K
AU - Munsey, M
AU - Mikus, C R
AU - David, R M
AU - Bralley, J A
AU - Church, T S
PY - 2009
Y1 - 2009
N2 - It is well established that the ingestion of the omega-3 (N3) fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) positively benefit a variety of health indices. Despite these benefits the actual intake of fish derived N3 is relatively small in the United States. The primary aim of our study was to examine a technology capable of delivering omega-3 fatty acids in common foods via microencapsulation (MicroN3) in young, healthy, active participants who are at low risk for cardiovascular disease. Accordingly, we randomized 20 participants (25.4 +/- 6.2 y; 73.4 +/- 5.1 kg) to receive the double blind delivery of a placebo-matched breakfast meal (~2093 kJ) containing MicroN3 (450-550 mg EPA/DHA) during a 2-week pilot trial. Overall, we observed no differences in overall dietary macronutrient intake other than the N3 delivery during our treatment regimen. Post-test ANOVA analysis showed a significant elevation in mean (SE) plasma DHA (91.18 +/- 9.3 vs. 125.58 +/- 11.3 umol/L; P
AB - It is well established that the ingestion of the omega-3 (N3) fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) positively benefit a variety of health indices. Despite these benefits the actual intake of fish derived N3 is relatively small in the United States. The primary aim of our study was to examine a technology capable of delivering omega-3 fatty acids in common foods via microencapsulation (MicroN3) in young, healthy, active participants who are at low risk for cardiovascular disease. Accordingly, we randomized 20 participants (25.4 +/- 6.2 y; 73.4 +/- 5.1 kg) to receive the double blind delivery of a placebo-matched breakfast meal (~2093 kJ) containing MicroN3 (450-550 mg EPA/DHA) during a 2-week pilot trial. Overall, we observed no differences in overall dietary macronutrient intake other than the N3 delivery during our treatment regimen. Post-test ANOVA analysis showed a significant elevation in mean (SE) plasma DHA (91.18 +/- 9.3 vs. 125.58 +/- 11.3 umol/L; P
UR - http://www.scopus.com/inward/record.url?scp=67651243814&partnerID=8YFLogxK
UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694142/pdf/1550-2783-6-12.pdf
UR - http://dx.doi.org/10.1186/1550-2783-6-12
U2 - 10.1186/1550-2783-6-12
DO - 10.1186/1550-2783-6-12
M3 - Article
SN - 1550-2783
VL - 6
JO - Journal of the International Society of Sports Nutrition
JF - Journal of the International Society of Sports Nutrition
IS - 1
M1 - 12
ER -
